Transfusion Safety: Where Are We Today?
- 1 November 2005
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1054 (1), 325-341
- https://doi.org/10.1196/annals.1345.040
Abstract
Over the past decades, the incidence of clinically significant transfusion-transmitted diseases has been dramatically reduced. These reductions have occurred because of a multifocal approach to the collection, processing, and release of blood and blood components. Research has focused on characterizing specific pathogens and their infectious patterns, especially the early viremic phase. Donor motivation and characteristics have been investigated, and restrictive eligibility criteria have been established. Regulatory oversight has been strengthened in the United States and hemovigilance systems established in many countries of the European Union, Canada, and Japan to identify new and emerging infectious and noninfectious transfusion risks. Such systems are required because many emerging pathogens will elude the stringent and sensitive donor testing already in place which, unfortunately, requires advanced technologies. Despite the remarkable progress, the processes of delivering a transfusion to a patient provide additional opportunity for risk, but have been less- well studied and the solutions have been less-well defined. Specific areas of concern include the collection and correct identification of patient samples, selection of modified or unique products, blood administration process, and establishment of specific indications for transfusion. In this chapter, we review the status of transfusion safety in the United States and discuss some emerging infectious and noninfectious risks of transfusion that will become future areas for basic and translational research. The disparities that exist in blood safety in developing countries' red cell alloimmunization and autoimmunity will not be covered.Keywords
This publication has 28 references indexed in Scilit:
- A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donorsTransfusion, 2005
- ES08.02 Bacterial contamination of cellular blood components: risks, sources and controlVox Sanguinis, 2004
- Consensus conference on vCJD screening of blood donors: report of the panelTransfusion, 2004
- White blood cell‐containing allogeneic blood transfusion, postoperative infection and mortality: a meta‐analysis of observational ‘before‐and‐after’ studiesVox Sanguinis, 2004
- Transfusion‐transmitted bacterial infectionin the United States, 1998 through 2000Transfusion, 2001
- Prevalence and Clinical Outcome of Hepatitis C Infection in Children Who Underwent Cardiac Surgery before the Implementation of Blood-Donor ScreeningNew England Journal of Medicine, 1999
- Histopathology of the liver in children with chronic hepatitis C viral infectionHepatology, 1998
- Acute Non-A–E Hepatitis in the United States and the Role of Hepatitis G Virus InfectionNew England Journal of Medicine, 1997
- Transfusion‐transmitted human parvovirus B19 infection in a thalassemic patientTransfusion, 1995
- Prevalence of antibodies to human immunodeficiency virus type 1 among blood donors prior to screening, The Transfusion Safety Study/NHLBI Donor RepositoryTransfusion, 1989